Whether the benefits that glycoprotein IIb/IIIa inhibitors confer in patients who undergo baremetal stent implantation extend to drug-eluting stents is unknown. We performed a prespecified subgroup analysis of the TAX...Whether the benefits that glycoprotein IIb/IIIa inhibitors confer in patients who undergo baremetal stent implantation extend to drug-eluting stents is unknown. We performed a prespecified subgroup analysis of the TAXUS IV study population to examine the effect of procedural glycoprotein IIb/IIIa inhibition during paclitaxel-eluting stent implantation on periprocedural creatine kinase-MB(CK-MB) levels. Glycoprotein(GP)IIb/IIIa inhibitors were administered to 57.7%of patients who had been randomized to receive the TAXUS stent and to 56.7%of those who had been randomized to receive the control stent. Among patients who received the TAXUS stent, the rate of CKMB increases of >3 times the normal level was 2.6-fold higher in those who received a GP IIb/IIIa inhibitor than in those who did not(11.4%vs 4.4%, p=0.0015). Composite rates of major adverse cardiac events and target vessel failure were also higher at 1 month in the GP IIb/IIIa group. By multivariate analysis, use of GP IIb/IIIa inhibitors during stenting with the TAXUS stent was an independent predictor of CK-MB increases >3 times the normal level. Further studies are warranted.展开更多
文摘Whether the benefits that glycoprotein IIb/IIIa inhibitors confer in patients who undergo baremetal stent implantation extend to drug-eluting stents is unknown. We performed a prespecified subgroup analysis of the TAXUS IV study population to examine the effect of procedural glycoprotein IIb/IIIa inhibition during paclitaxel-eluting stent implantation on periprocedural creatine kinase-MB(CK-MB) levels. Glycoprotein(GP)IIb/IIIa inhibitors were administered to 57.7%of patients who had been randomized to receive the TAXUS stent and to 56.7%of those who had been randomized to receive the control stent. Among patients who received the TAXUS stent, the rate of CKMB increases of >3 times the normal level was 2.6-fold higher in those who received a GP IIb/IIIa inhibitor than in those who did not(11.4%vs 4.4%, p=0.0015). Composite rates of major adverse cardiac events and target vessel failure were also higher at 1 month in the GP IIb/IIIa group. By multivariate analysis, use of GP IIb/IIIa inhibitors during stenting with the TAXUS stent was an independent predictor of CK-MB increases >3 times the normal level. Further studies are warranted.
